MTOR and neoplasm: Similarly, PI3K/AKT/mTOR activation, which promotes tumor cell survival during chemotherapy, concurrently upregulates immunosuppressive cytokines such as IL-6, thereby fostering a hostile tumor microenvironment (TIME) to T-cell activity.